Though the Board didn't appoint Jenn from the outset (as she hadn't been a CEO / MD before), I think this was probably something they told Jenn was on the table when they poached her from Kite Pharma last year... and she'd be given the opportunity to lead this company if she was able to demonstrate she could do the job. She has obviously made this role her own and demonstrated behind the scenes that she is highly competent and able to inspire her team and lead this company to achieve wonderful things.
Jenn's background is primarily commercial strategy, operations and marketing and with 20 years in the cell therapy/oncology space, and being the Cell Therapy commercial lead at Celgene and Head of Global Marketing, Analytics and Commercial Operations at Kite Pharma... these clearly translate extremely well to a CEO / MD role of CHM, so it's wonderful to see this eventuate.
CHM Price at posting:
31.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)